Plain-English translation of NCT07138547 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lymphoma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a medication called eliglustat combined with existing lymphoma immunotherapy treatments (either a targeted antibody called brentuximab vedotin or CAR-T cell therapy) in people with CD30-positive lymphoma. The researchers believe that eliglustat may help the immune therapy work better by changing how cancer cells hide from the immune system. The trial aims to see if this combination is safe and more effective than immunotherapy alone.
Current lymphoma immunotherapies don't work well enough for everyone—some patients don't respond at all, and others lose their response over time. Early research suggests that this medication might help the immune system recognize and attack cancer cells more effectively by removing a protective coating that tumors use to escape treatment.
You likely qualify if…
You likely don't qualify if…
You would take the medication twice daily for the first 2 weeks, then switch to taking it every other week for up to 24 weeks (and possibly longer if you're benefiting). At the same time, you'll receive the immunotherapy—either an infusion of brentuximab vedotin every 3 weeks or a one-time CAR-T cell therapy infusion, depending on which group you're assigned to. You'll have regular clinic visits to check your health, monitor how well the treatment is working, and watch for any side effects. The entire study lasts up to 96 weeks.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China